Agarwal S.K., Lee Burns A., Sukhodolets K.E., et al. Molecular pathology of the MEN1 gene. Ann. N. Y. Acad. Sci. 2004, 1014:189-198.
Larsson C., Skogseid B., Oberg K., et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988, 332(6159):85-87. March 3.
Chandrasekharappa S.C., Guru S.C., Manickam P., et al. Positional cloning of the gene for multiple endocrine neoplasia- type 1. Science 1997, 276(5311):404-407. April 18.
Scacheri P.C., Davis S., Odom D.T., et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet. 2006, 2(4):e51. April.
Agarwal S.K., Impey S., McWeeney S., et al. Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation. Neoplasia 2007, 9(2):101-107. February.
Lemos M.C., Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 2008, 29(1):22-32. January.
Vergès B., Boureille F., Goudet P., et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab. 2002, 87(2):457-465. February.
Beckers A., Betea D., Valdes Socin H., et al. The treatment of sporadic versus MEN1-related pituitary adenomas. J. Int. Med. 2003, 253:599-605.
Boikos S.A., Stratakis C.A. Carney complex: the first 20 years. Curr. Opin. Oncol. 2007, 19:24-29.
Stratakis C.A., Kirschner L.S., Carney J.A. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J. Clin. Endocrinol. Metab. 2001, 86(9):4041-4046.
Casey M., Mah C., Merliss A.D., et al. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation 1998, 98:2560-2566.
Fritz A., Walch A., Piotrowska K., et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res. 2002, 62(11):3048-3051. June 1.
Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. USA 2006, 103(42):15558-15563. October 17.
Georgitsi M., Raitila A., Karhu A., et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 2007, 92(8):3321-3325.
Teh B.T., Kytölä S., Farnebo F., et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J. Clin. Endocrinol. Metab. 1998, 83:2621-2626.
Poncin J., Abs R., Velkeniers B., et al. Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. Hum. Mut. 1999, 13:54-60.
Luccio-Camelo D.C., Une K.N., Ferreira R.E., et al. A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur. J. Endocrinol. 2004, 150(5):643-648. May.
Vierimaa O., Georgitsi M., Lehtonen R., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312(5777):1228-1230.
Karga H.J., Alexander J.M., Hedley-Whyte E.T., et al. Ras mutations in human pituitary tumors. J. Clin. Endocrinol. Metab. 1992, 74:914-919.
Pei L., Melmed S., Scheithauer B., et al. H-ras mutations in human pituitary carcinoma metastases. J. Clin. Endocrinol. Metab. 1994, 78:842-846.
Zhang X., Horwitz G.A., Heaney A.P., et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 1999, 84:761-767.
Minematsu T., Suzuki M., Sanno N., et al. PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocr. Pathol. 2006, 17:143-153.
Hu N., Gutsmann A., Herbert D.C., et al. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994, 9:1021-1102.
Zhu J., Leon S.P., Beggs A.H., et al. Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus. J. Clin. Endocrinol. Metab. 1994, 78:922-927.
Simpson D.J., Hibberts N.A., McNicol A.M., et al. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 2000, 60:1211-1216.
Hibberts N.A., Simpson D.J., Bicknell J.E., et al. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin. Cancer Res. 1999, 5:2133-2139.
Simpson D.J., Fryer A.A., Grossman A.B., et al. Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas. Carcinogenesis 2001, 22:1801-1807.
Woloschak M., Yu A., Xiao J., et al. Frequent loss of the P16INK4a gene product in human pituitary tumors. Cancer Res. 1996, 56:2493-2496.
Farrell W.E., Simpson D.J., Bicknell J.E., et al. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res. 1997, 57:2703-2709.
Fero M.L., Rivkin M., Tasch M., et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996, 85:733-744.
Pagotto U., Arzberger T., Theodoropoulou M., et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 2000, 60:6794-6799.
Theodoropoulou M., Zhang J., Laupheimer S., et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2000, 66:1576-1582.
Ezzat S., Asa S.L. Mechanisms of disease: the pathogenesis of pituitary tumors. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2:220-230.
Zhang X., Zhou Y., Mehta K.R., et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J. Clin. Endocrinol. Metab. 2003, 88:5119-5126.
Zhao J., Dahle D., Zhou Y., et al. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J. Clin. Endocrinol. Metab. 2005, 90:2179-2186.
Zhang X., Sun H., Danila D.C., et al. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J. Clin. Endocrinol. Metab. 2002, 87:1262-1267.
Paez-Pereda M., Giacomini D., Refojo D., et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1034-1039.
Scheithauer B.W., Laws E.R., Kovacs K., et al. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin. Diagn. Pathol. 1987, 4(3):205-211.
Daly A., Rixhon M., Adam C., et al. High prevalence of pituitary adenomas: a cross sectional study in the Province of Liege, Belgium. J. Clin. Endocrinol. Metab. 2006, 91:4769-4775.
Erdheim J. Zur normalen und pathologischen Histologic der Glandula thyreoidea, parathyreoidea und Hypophysis. Beitr. z. path. Anat. u. z. allg. Path. 1903, 33:158-233.
Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am. J. Med. 1954, 16(3):363-371.
Skogseid B., Eriksson B., Lundqvist G., et al. Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J. Clin. Endocrinol. Metab. 1991, 73:281-287.
Burgess J.R., Shepherd J.J., Parameswaran V., et al. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN1): clinical, biochemical, and radiological features of pituitary disease in a large MEN1 kindred. J. Clin. Endocrinol. Metab. 1996, 81:2642-2646.
Marx S., Spiegel A.M., Skarulis M.C., et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann. Intern. Med. 1998, 129:484-494.
Zhuang Z., Ezzat S.Z., Vortmeyer A.O., et al. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res. 1997, 57(24):5446-5451. December 15.
Poncin J., Stevenaert A., Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. Eur. J. Endocrinol. 1999, 140(6):573-576. June.
Wenbin C., Asai A., Teramoto A., et al. Mutations of the MEN1 tumor suppressor gene in sporadic pituitary tumors. Cancer Lett. 1999, 142(1):43-47. July 19.
Schmidt M.C., Henke R.T., Stangl A.P., et al. Analysis of the MEN1 gene in sporadic pituitary adenomas. J. Pathol. 1999, 188(2):168-173. June.
Fukino K., Kitamura Y., Sanno N., et al. Analysis of the MEN1 gene in sporadic pituitary adenomas from Japanese patients. Cancer Lett. 1999, 144(1):85-92. September 20.
Asa S.L., Somers K., Ezzat S. The MEN-1 gene is rarely down-regulated in pituitary adenomas. J. Clin. Endocrinol. Metab. 1998, 83(9):3210-3212. September.
Tanaka C., Kimura T., Yang P., et al. Analysis of loss of heterozygosity on chromosome 11 and infrequent inactivation of the MEN1 gene in sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 1998, 83(8):2631-2634. August.
Tanaka C., Yoshimoto K., Yamada S., et al. Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese. J. Clin. Endocrinol. Metab. 1998, 83(3):960-965. March.
Theodoropoulou M., Cavallari I., Barzon L., et al. Differential expression of menin in sporadic pituitary adenomas. Endocr. Relat. Cancer 2004, 11(2):333-344. June.
Beckers A., Abs R., Reyniers E., et al. Variable regions of chromosome 11 loss in different pathological tissues of a patient with the multiple endocrine neoplasia type I syndrome. J. Clin. Endocrinol. Metab. 1994, 79(5):1498-1502. November.
Farid N.R., Buehler S., Russell N.A., et al. Prolactinomas in familial multiple endocrine neoplasia syndrome type I. Relationship to HLA and carcinoid tumors. Am. J. Med. 1980, 69(6):874-880. December.
Olufemi S.E., Green J.S., Manickam P., et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum. Mutat. 1998, 11(4):264-269.
Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 2001, 86(12):5658-5671.
Carney J.A., Hruska L.S., Beauchamp G.D., et al. Dominant inheritance of the complex of myxomas, spotty pigmentation and endocrine overactivity. Mayo. Clinic. Proc. 1985, 61:165-172.
Stratakis C.A., Kirschner L.S., Carney J.A. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J. Clin. Endocrinol. Metab. 2001, 86(9):4041-4046.
Casey M., Mah C., Merliss A.D., et al. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation 1998, 98:2560-2566.
Stratakis C.A., Carney J.A., Lin J.P., et al. Carney complex, a familial multiple endocrine neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J. Clin. Invest. 1996, 97:699-705.
Veugelers M., Wilkes D., Burton K., et al. Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc. Natl. Acad. Sci. USA. 2004, 101(39):14222-14227. September 28.
Kirschner L.S., Sandrini F., Monbo J., et al. Genetic heterogeneity and spectrum of mutations of the PPKAR1A gene in patients with the Carney complex. Hum. Mol. Genet. 2000, 9:3037-3046.
Bossis I., Stratakis C.A. Minireview: PRKAR1: normal and abnormal functions. Endocrinology 2004, 145:5452-5458. December.
Griffin K.J., Kirschner L.S., Matyakhina L., et al. Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. Cancer Res. 2004, 64(24):8811-8815. December 15.
Griffin K.J., Kirschner L.S., Matyakhina L., et al. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours. J. Med. Genet. 2004, 41(12):923-931. December.
Stergiopoulos S.G., Stratakis C.A. Human tumors associated with Carney complex and germline PPKAR1A mutations: a protein kinase A disease. FEBS Lett. 2003, 546:59-64.
Pack S.D., Kirschner L.S., Pak E., et al. Genetic and histological studies of somatomammotropic tumors in patients with the "Complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). J. Clin. Endo. Metab. 2000, 85:3860-3865.
Kurtkaya-Yapicier O., Scheithauer B.W., Carney J.A., et al. Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study. Ultrastruct. Pathol. 2002, 26(6):345-353. November-December.
Kaltsas G.A., Kola B., Borboli N., et al. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin. Endocrinol. (Oxf.) 2002, 57(4):443-448. October.
Fritz A., Walch A., Piotrowska K., et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res. 2002, 62(11):3048-3051. June 1.
Piotrowska K., Pellegata N.S., Rosemann M., et al. Mapping of a novel MEN-like syndrome locus to rat chromosome 4. Mamm. Genome. 2004, 15(2):135-141. February.
Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. USA. 2006, 103(42):15558-15563. October 17.
Georgitsi M., Raitila A., Karhu A., et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 2007, 92(8):3321-3325.
Ozawa A., Agarwal S.K., Mateo C.M., et al. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J. Clin. Endocrinol. Metab. 2007, 92(5):1948-1951. May.
Beckers A., Daly A.F. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur. J. Endocrinol. 2007, 157(4):371-382. October.
Villa C., Magri F., Morbini P., et al. Silent familial isolated pituitary adenomas: histopathological and clinical case report. Endocr. Pathol. 2008, 19(1):40-46. Spring.
Leontiou C.A., Gueorguiev M., van der Spuy J., et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 2008, 93(6):2390-2401. June.
Daly A.F., Jaffrain-Rea M.L., Ciccarelli A., et al. Clinical characterization of familial isolated pituitary adenomas. J. Clin. Endocrinol. Metab. 2006, 91(9):3316-3323. September, Epub 2006 Jun 20.
Ciccarelli A., Daly A.F., Beckers A. The epidemiology of prolactinomas. Pituitary 2005, 8(1):3-6.
Daly A.F., Vanbellinghen J.F., Khoo S.K., et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab. 2007, 92(5):1891-1896. May.
Iwata T., Yamada S., Mizusawa N., et al. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin. Endocrinol. (Oxf.) 2007, 66(4):499-502. April.
Toledo R.A., Lourenco D.M., Liberman B., et al. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J. Clin. Endocrinol. Metab. 2007, 92(5):1934-1937. May.
Yu R., Bonert V., Saporta I., et al. AIP variants in sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 2006, 91(12):5126-5129. December.
Barlier A., Vanbellinghen J.F., Daly A.F., et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 2007, 92(5):1952-1955. May, Epub 2007 Feb 13.
Georgitsi M., Raitila A., Karhu A., et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl. Acad. Sci. USA. 2007, 104(10):4101-5105. March 6.
Georgitsi M., Karhu A., Winqvist R., et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br. J. Cancer 2007, 96(2):352-356. January 29.
Petrulis J.R., Perdew G.H. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem. Biol. Interact. 2002, 141(1-2):25-40.
Bell D.R., Poland A. Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of hsp90. J. Biol. Chem. 2000, 275(46):36407-36414.
Carver L.A., LaPres J.J., Jain S., et al. Characterization of the Ah receptor-associated protein, ARA9. J. Biol. Chem. 1998, 273(50):33580-33587.
Meyer B.K., Perdew G.H. Characterization of the AhR-hsp90-XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Biochemistry 1999, 38(28):8907-8917.
Bolger G.B., Peden A.H., Steele M.R., et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J. Biol. Chem. 2003, 278(35):33351-33363. August 29.
de Oliveira S.K., Hoffmeister M., Gambaryan S., et al. Phosphodiesterase 2A forms a complex with the co- chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J. Biol. Chem. 2007, 282(18):13656-13663. May 4.
Lin B.C., Sullivan R., Lee Y., et al. Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J. Biol. Chem. 2007, 282(49):35924-35932. December 7.
Lin B.C., Nguyen L.P., Walisser J.A., et al. A hypomorphic allele of aryl-hydrocarbon receptor-associated-9 produces a phenocopy of the Ahr null. Mol. Pharmacol. 2008, 74(5):1367-1371. November.
Pesatori A., Baccarelli A., Consonni D., et al. Aryl hydrocarbon receptor interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. Eur. J. Endocrinol. 2008, 159(6):699-703. December.
Naves L.A., Daly A.F., Vanbellinghen J.F., et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur. J. Endocrinol. 2007, 157(4):383-391. October.
Georgitsi M., Heliövaara E., Paschke R., et al. Large genomic deletions of aryl hydrocarbon receptor interacting protein (AIP) gene in pituitary adenoma predisposition. J. Clin. Endocrin. Metab. 2009, 93(10):4146-4151. October.
M.L. Jaffrain Rea, M. Angelini, D. Gargano, et al., Expression of aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor interacting protein (AIP) in pituitary adenomas: pathological and clinical implications, Endocr. Relat. Cancer (2009 June 25), DOI: 10.1677/ERC-09-0094.
